E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Upper facial lines (horizontal forehead lines, glabellar frown lines, and lateral periorbital lines) |
|
E.1.1.1 | Medical condition in easily understood language |
Moderate to severe wrinkles in the upper face |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Skin and Connective Tissue Diseases [C17] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10040954 |
E.1.2 | Term | Skin wrinkling |
E.1.2 | System Organ Class | 10040785 - Skin and subcutaneous tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate the safety and tolerability of 54 to 64 Units [U] of NT 201 intramuscularly administered in subjects with moderate to severe upper facial lines [UFL] during repeat-dose treatment of these lines. |
|
E.2.2 | Secondary objectives of the trial |
To investigate the efficacy of simultaneous treatment of moderate to severe UFL during repeat-dose injection. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Main inclusion criteria
• Signed written informed consent obtained from subject.
• Outpatients (male or female) 18 years of age or older.
• HFL, GFL, and symmetrical LPL of moderate to severe intensity at maximum contraction as assessed by the investigator according to the Merz Aesthetics Scales.
• Stable medical condition.
Eligibility criteria for reinjection
• Subjects must have relapsed to at least moderate intensity at maximum contraction in all three treated areas as assessed by the investigator.
• Absence of ongoing adverse events related to toxin spread.
• No infection and/or inflammation in the area of the planned injection points. |
|
E.4 | Principal exclusion criteria |
Main exclusion criteria
• Previous treatment with any facial cosmetic procedure (e.g. dermal filling, chemical peeling, photo rejuvenation) in the forehead, glabellar, and/or periorbital area within the last 8 months before injection.
• Previous treatment with Botulinum toxin of any serotype in the forehead, glabellar, and/or periorbital area within the last 6 months before injection.
• Any previous insertion of permanent material in the forehead, glabellar, and/or periorbital area (regardless of the time between previous treatment and this study).
• Planned treatment with Botulinum toxin of any serotype in the face during the study period.
• Any other planned facial cosmetic procedure in the face during the study period.
• Very severe lines (HFL, GFL, and/or LPL) at maximum contraction as assessed by the investigator according to the Merz Aesthetics Scales.
• Inability to substantially lessen UFL (HFL, GFL, LPL) by physically spreading them apart.
• Any surgery or scars in the forehead, glabellar, or periorbital area.
• Marked facial asymmetry.
• Excessively thick sebaceous skin or hypertrophic muscles in the upper third part of the face.
• Eyelid ptosis.
• Marked brow ptosis.
• History of facial nerve palsy.
• Any infection and/or inflammation at the planned injection points.
• Bleeding disorders or regular intake of drugs with anticoagulative effect within the last ten days prior to injection until four days after injection.
• Any medical condition that may put the subject at increased risk with exposure to NT 201, including myasthenia gravis, Lambert-Eaton-Syndrome, amyotrophic lateral sclerosis or any other disorder that might interfere with neuromuscular function.
• Intake of any of the forbidden concomitant medication, e.g. aminoglycoside antibiotics, or other agents that might interfere with neuromuscular function (e.g. D-penicillinamine, curarine-type muscle relaxants, succinylcholine) or might interfere with the action of BoNT A (e.g. chloroquine) within 14 days prior to injection. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary safety variables:
• Incidence of Treatment Emergent Adverse Events [TEAEs] during the overall period of the study.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Secondary safety variables:
• Incidence of Treatment Emergent Adverse Events [TEAEs] per treatment cycle.
• Incidence of Treatment Emergent AEs of special interest [TEAESIs] during the overall period of the study and per treatment cycle.
Secondary efficacy variables:
• Percentage of responders at maximum contraction for the three treated areas individually at day 30 of each injection cycle as assessed by the investigator according to the Merz Aesthetics Scales, i.e. a score of none (0) or mild (1). The periorbital region/crow’s feet will be assessed separately for each facial side (left and right) and both sides have to respond according to the previous responder definition
• Percentage of responders at day 30 of each injection cycle for the overall appearance of the upper face, as self-assessed by the subject according to the Global Impression of Change Scale, i.e. a score of much improved (+2) or very much improved (+3). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Secondary efficacy variables at day 30 of each injection cycle |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 12 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of study is defined as the last visit of the last subject. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |